文献速递肿瘤 PET/CT

基于PSA分层的[68Ga]THP-PSMA PET/CT在前列腺癌根治术后生化复发患者中的检出率

PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-01-07

回顾性分析99例前列腺癌根治术后生化复发患者,[68Ga]THP-PSMA PET/CT总检出率为52.5%,检出率随PSA升高而增加,PSA≥10 ng/mL时为94.1%,2至<10 ng/mL时为77.3%;延迟3小时显像仅在2%的扫描中额外发现病灶。

要点

  • PSA≥2 ng/mL时[68Ga]THP-PSMA PET/CT检出率较高,PSA 2至<10 ng/mL为77.3%,≥10 ng/mL为94.1%。
  • PSA<2 ng/mL各分层检出率较低,1至<2 ng/mL为54.5%,0.5至<1 ng/mL为14.3%。
  • Gleason评分≥8分和接受雄激素剥夺治疗的患者检出率更高。

核心结论

  • [68Ga]THP-PSMA PET/CT在前列腺癌生化复发且PSA≥2 ng/mL的患者中显示适宜的检出率,但检出率低于既往评估其他PSMA配体的研究;作者认为尤其需要在低PSA患者中进行前瞻性直接放射性示踪剂比较研究以评估不同PSMA配体的相对性能。

研究设计与样本

  • 回顾性分析连续纳入的99例前列腺癌根治术后生化复发、转诊行[68Ga]THP-PSMA PET/CT评估的患者。
  • 患者接受标准全身PET/CT(注射后1小时),随后进行腹部延迟显像(注射后3小时)。

主要发现

  • 52例(52.5%)患者PET图像上至少发现一个提示复发或转移性前列腺癌的病灶。
  • 检出率随PSA水平升高而增加:PSA≥10 ng/mL为94.1%,2至<10 ng/mL为77.3%,1至<2 ng/mL为54.5%,0.5至<1 ng/mL为14.3%,>0.2至<0.5 ng/mL为20.0%,0.01至0.2 ng/mL为22.2%。
  • 转移灶中[68Ga]THP-PSMA摄取(SUV)随时间下降,而靶本比(TBR)改善。
  • 延迟3小时显像在2%的[68Ga]THP-PSMA PET/CT扫描中单独发现了病理学表现。
  • Gleason评分≥8分的患者检出率更高(P=0.02),接受雄激素剥夺治疗的患者检出率更高(P=0.003)。

局限性

  • 作者指出检出率低于既往评估其他PSMA配体的研究,并认为尤其需要在低PSA患者中进行前瞻性直接放射性示踪剂比较研究以评估不同PSMA配体的相对性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: [68Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of 68Ga3+ at low concentration, room temperature and over a wide pH range, using direct elution from a 68Ge/68Ga-generator. We evaluated the clinical detection rates of [68Ga]THP-PSMA PET/CT in patients with biochemically recurrent prostate cancer after prostatectomy. METHODS: Consecutive patients (n=99) referred for evaluation of biochemical relapse of prostate cancer by [68Ga]THP-PSMA PET/CT were analyzed retrospectively. Patients underwent a standard whole-body PET/CT (1 h p.i.), followed by delayed (3 h p.i.) imaging of the abdomen. PSA-stratified cohorts of positive PET/CT results, standardized uptake values (SUVs) and target-to-background ratios (TBRs) were analyzed, and compared between standard and delayed imaging. RESULTS: At least one lesion suggestive of recurrent or metastatic prostate cancer was identified on PET images in 52 patients (52.5%). Detection rates of [68Ga]THP-PSMA PET/CT increased with increasing PSA level: 94.1% for a PSA value of ≥10 ng/mL, 77.3% for a PSA value of 2 to <10 ng/mL, 54.5% for a PSA value of 1 to <2 ng/mL, 14.3% for a PSA value of 0.5 to <1 ng/mL, 20.0% for a PSA value of >0.2 to <0.5, and 22.2% for a PSA value of 0.01 to 0.2 ng/mL. [68Ga]THP-PSMA uptake (SUVs) in metastases decreased over time, whereas TBRs improved. Delayed imaging at 3 h p.i. exclusively identified pathologic findings in 2% of [68Ga]THP-PSMA PET/CT scans. Detection rate was higher in patients with a Gleason score ≥8 (P=0.02) and in patients receiving androgen deprivation therapy (P=0.003). CONCLUSIONS: In this study, [68Ga]THP-PSMA PET/CT showed suitable detection rates in patients with biochemical recurrence of prostate cancer and PSA levels ≥ 2 ng /mL. Detections rates were lower than in previous studies evaluating other PSMA ligands, though prospective direct radiotracer comparison studies are mandatory particularly in patients with low PSA levels to evaluate the relative performance of different PSMA ligands.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Derlin T, Schmuck S, Juhl C, et al. PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 29308527. doi:10.1007/s00259-017-3924-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。